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Introduction. Hypogonadism is one of the most common male endocrine problems. Although many treatments are
currently available, unmet need exists for new testosterone (T) replacement therapies that are simple to administer
and use, are safe, and mimic physiologic T levels.
Aim. The study aim was to determine the pharmacokinetics (PK), safety, and tolerability of T enanthate (TE)
administered via a novel single-use autoinjector system, which was designed to eject high-viscosity solutions from a
preﬁlled syringe ﬁtted with a ﬁve-eighths-inch 27-gauge needle.
Methods. Thirty-nine men with hypogonadism entered this dose-ﬁnding, open-label, parallel-group study. Patients
were washed out of their topical T regimens and randomized to receive 50 or 100 mg of subcutaneous (SC) TE
weekly. The reference group were patients with hypogonadism who were maintained on standard 200-mg intra-
muscular (IM) TE.
Main Outcome Measure. The primary outcome measure was the PK proﬁle of SC TE, analyzed in reference to T
levels used by the Food and Drug Administration to approve T products. Secondary outcome measures were safety
and tolerability assessments.
Results. Both doses of SC TE achieved normal average concentrations of serum T within a 168-h dosing interval
after injection. Concentration ranges were similar at all time points following 50-mg SC TE injections and following
the third injection in the 100-mg arm. Mean steady-state T concentration at week 6 was 422.4 and 895.5 ng/dL for
the 50- and 100-mg SC TE arms, respectively. SC TE demonstrated PK dose proportionality. SC TE restored
normal serum T with low variation relative to 200-mg IM without clinically signiﬁcant adverse events.
Conclusions. Administration of TE via this novel injection system restored T levels to normal range in men with
hypogonadism. SC TE dosed weekly demonstrated steady, dose-proportional measures of exposure and was well-
tolerated. Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone
enanthate delivered via a novel, prefilled single-use autoinjector: A phase II study. Sex Med 2015;3:269–279.
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Introduction
Hypogonadism in men is a deﬁciency in serumtestosterone (T) levels with symptoms sec-
ondary and responsive to T replacement [1,2].
Diagnosis may be made in men of any age [3].
Prevalence varies according to different reports, as
it is inﬂuenced by the nature of the populations
used in the study as well as the criteria used to
deﬁne both the study and reference populations.
According to one estimate, up to ﬁve million men
are afﬂicted with this disorder in the United States
and this number may reach 6.5 million by 2025
[3,4]. Use of T replacement therapy (TRT) has
increased in recent years [5]. Available TRTs in the
United States include intramuscular injections
(IM), transdermal, transbuccal and intranasal
applications, and implantable pellets. Selection of
treatment modality is often inﬂuenced by conve-
nience and cost of therapy [6–8]. TRT beneﬁts
patients with hypogonadism by restoring T to
physiologic levels, consequently improving mood,
increasing bone and muscle mass, reducing adipos-
ity, and improving libido and sexual function [9].
While TRT may beneﬁt many patients, there
are important class safety factors to consider. TRT
is contraindicated for patients with prostate and
male breast cancer [1]. T gels carry a warning due
to the potential for secondary exposure to those in
close contact with the patient [10]. A large volume,
long-acting formulation of T in oil injected IM
through a large bore needle carries a boxed
warning for pulmonary oil embolism [11]. Uncer-
tainty exists as to whether or not patients may
suffer adverse cardiovascular effects. Some
outcome studies have indicated that TRT is asso-
ciated with an increased risk of cardiovascular
adverse events (AEs) [12,13]. Meanwhile, other
outcome studies ﬁnd no effect or reductions in
cardiovascular events related to TRT [14,15], or
rather that decrease in T levels (T deﬁciency) is
associated with increased mortality and risk of car-
diovascular disease [16,17].
Drawbacks exist with each of the currently
available T delivery mechanisms. For example, IM
injections can be painful [18,19]; the discomfort
associated with large needle bore and length
required for manual IM injection of viscous oil
solutions can negatively impact patient compliance
[20]. Because ofﬁce visits are commonly recom-
mended by providers, there is inconvenience to
users. In addition, IM injection of T enanthate
(TE) in sesame oil (e.g., Delatestryl®) is often
administered in 200–400 mg doses every 2–4
weeks leading to peak and trough T levels outside
of physiologic range [21,22]. Resulting ﬂuctua-
tions may lead to mood swings and disturbances in
energy level [9,23]. Transdermal patches are com-
monly associated with skin reactions, which can
lead to discontinuation of therapy [24]. Gels carry
a risk of transference to women and children and
are considered messy and may have an unpleasant
odor to some users [10]. Nasally administered T
and oral TRT in development appear to require
multiple daily doses [25,26]. Oral TRT can cause
gastrointestinal side effects. Because there are
limitations to these delivery systems, patient com-
pliance with treatment is an issue and TRT
discontinuation rates are high [27]. Therefore,
weekly subcutaneous (SC) administration of TE in
oil solution, via a device optimized to inject highly
viscous solutions through a ﬁve-eighths-inch
27-gauge needle (Supplemental Figure S1), is pro-
posed as a viable alternative to other routes of
administration, such as IM delivery systems. The
objective of our phase II study was to assess the
steady-state pharmacokinetics (PK) of two
strengths of TE administered SC via a drug-device
combination, as a multiple-dose regimen, to evalu-
ate the possible utility of this modality for chronic
replacement therapy.
Aims
This was a multicenter, phase II, three-arm, open-
label, multi-dose, parallel-group study of two
dosing levels of TE to determine the PK proﬁle of
a novel drug-device combination product to
administer SC TE in oil once weekly.
Methods
Study Population
Male patients (18–75 years) with a history of
physician-diagnosed hypogonadism of any etiol-
ogy and with serum total T (TT) levels
<300 ng/dL recorded on two occasions at least 1
week apart were eligible for this study. Patients
were required to be in good general health without
signiﬁcant comorbidities and with a body mass
index (BMI) between 18 and 32 kg/m2. All patients
were provided complete information of all AEs
related to T and were subsequently required to
provide written informed consent to be screened
for all study requirements and restrictions.
Patients were excluded if they had normal T levels
(>300 ng/dL) or if they were deemed to have any
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clinically signiﬁcant medical condition, which, in
the opinion of the investigator, made the patient
an unsuitable candidate for enrollment in the
study. All 39 patients enrolled were included in the
safety and PK populations. Investigators are listed
in Supplemental Table S1. Summary of prior T
treatment is provided in Supplemental Table S2.
Study Design
This was a three-arm, open-label, multi-dose,
parallel-group, phase II study (ClinicalTrials.gov
Identiﬁer: NCT01887418) of the PK, safety,
and tolerability of TE administered SC via
autoinjector or IM via needle and syringe. The
study design is summarized in Figure 1. Of the 86
patients screened between August 28, 2013, and
November 1, 2013, 39 were dosed. Reasons for
screen failure are provided in Supplemental Table
S3. Patients randomized to 50 or 100 mg SC TE
must have never previously received TRT or had
to be washed out of any prior therapy before ﬁrst
dose. Any patient that had received buccal or
transdermal T at the time of the screening visit
were washed out of therapy for at least 2 weeks,
assessed for study eligibility, and randomized to
treatment with SC TE (50 or 100 mg in 0.5 mL).
Patients receiving IM TE treatment at time of
study entry were assessed for study eligibility for
the IMTE reference group. The SC arms received
their dose of the preservative-free formulation of
TE via an autoinjector device designed to deliver
high-viscosity solutions through a small bore
needle. All study medication was administered by
study personnel. Patients in the IM group, who
were already at steady-state, received a single
1-mL IM injection of 200 mg/mL of TE in sesame
oil (West-Ward Pharmaceutical Corp, Eatontown,
NJ, USA) via needle and syringe. During the treat-
ment period, the SC treatment arms received their
respective dose once weekly over 6 weeks. Institu-
tional review boards of participating centers
approved the study design. The study was con-
ducted in accordance with the Declaration of Hel-
sinki and with all applicable laws and regulations of
the locale and country where the study was con-
ducted, and was in compliance with Good Clinical
Practice Guidelines. Informed consent was
obtained from the patients.
PK Profile Assessment
Seven-day PK proﬁles were collected for each
patient in the SC TE treatment arms at weeks 1
and 5 and the full PK proﬁle following the sixth
dose. Pre-dose trough and 24 hours post-dose
samples were collected at each of the 6 weekly
treatment visits. For patients in the IM TE group,
a PK proﬁle was collected through week 4.
Laboratory Tests, Biomarker Analyses, and
Safety Analyses
Sensitive and speciﬁc liquid chromatography–
tandem mass spectrometry (LC–MS/MS) assays
for the quantiﬁcation of T, dihydrotestosterone
(DHT), and estradiol were developed, validated
and performed by Medpace Bioanalytical Labora-
tories (Cincinnati, OH, USA) [28,29].
Safety data collected included treatment-
emergent AEs (TEAEs), vital signs, injection site
assessments (ISA), prostate exam, 12-lead electro-
cardiogram, and laboratory assessments. The col-
lection of all treatment TEAEs and determination
of frequency of TEAEs for each organ system
allowed for deciphering of any treatment-related
patterning of TEAEs. AEs were coded using
MedDRA version 16.0. An AE was considered to
be a TEAE if the event started on or after the ﬁrst
dose of study medication. ISA were performed 0.5,
1.0, and 24.0 hours post-dose after each injection.
86 Screened
39
Randomized
39
Treated
15 receiving
100 mg SC TE
15
Completed
0
Withdrawn
14 receiving
50 mg SC TE
14
Completed
0
Withdrawn
10 receiving
200 mg IM TE
9
Completed
1
Withdrawn*
Figure 1 Study design. *One person
in the 200 mg intramuscular (IM) tes-
tosterone enanthate (TE) arm discon-
tinued due to personal reasons
unrelated to study medication.
SC = subcutaneous
PK of SC TE Delivered via Novel Autoinjector 271
Sex Med 2015;3:269–279© 2015 Antares Pharma, Inc. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
Parameters for documentation included erythema,
induration, bleeding, hematoma, ecchymosis,
pinprick/needle mark, device pressure mark, and
the presence of itching and pain. For patients who
reported pain or itch on injection, pain/itch was
rated using a visual analog scale (VAS) (1, barely
noticeable, to 10, worst they have ever experienced).
For the erythema, induration, hematoma, ecchy-
mosis, and pressure mark, measurements of the
diameter at the widest point were measured to the
nearest mm. An injection site adverse reaction was
reported for observations measuring ≥25 mm or
persisting ≥24 hours. Routine safety laboratory
and prostate-speciﬁc antigen testing were per-
formed. Clinical laboratory evaluations included
hematology, biochemistry, and urinalysis. These
safety laboratory tests were performed at screen-
ing, week 3 for the SC treatment arms, week 4 for
the IM treatment group, and at the end of the
study.
Determination of Sample Size and Statistic Analyses
Sample size was determined by study objectives,
as opposed to statistic power calculations, and
was planned to ensure that at least 24 patients
completed the study. Up to 45 patients could be
enrolled and the ﬁnal population included 14
patients in the 50-mg SC TE arm, 15 in the
100-mg SC TE treatment arm, and 10 in the IM
treatment group. PK and safety analyses were
performed in those patients who received at least
one dose of study medication. For evaluation of
PK parameters, relative bioavailability was deter-
mined from point estimates of the geometric
least-squares mean ratios and associated 90%
conﬁdence intervals. Creation of datasets and sta-
tistic analyses were performed using SAS®
version 9.3 (SAS Institute Inc., USA).
Main Outcome Measures
The primary endpoint was to quantify measures of
exposure to two dose levels of a SC TE formula-
tion over 6 weeks, analyzed in reference to T levels
used by the Food and Drug Administration (FDA)
to approve T products. Blood sampling following
dosing allowed for determination of the PK
parameters of the regimen including area under
the concentration–time curve from time zero
to immediately prior to the next weekly dose
(AUC0–168 h), from which the average concentra-
tion over the 7-day dosing interval (Cavg0–168 h), and
maximum observed plasma concentration (Cmax)
was derived. Secondary endpoints included safety
and tolerability parameters over the 6-week treat-
ment period.
Results
Patient Disposition and Baseline Demographics/
Clinical Characteristics
Thirty-nine patients were enrolled (Table 1) and
evaluated for safety and PK analyses. Thirty-eight
of 39 (97.4%) patients completed this study; one
patient in the IM treatment group withdrew from
the study after dose administration for reasons
unrelated to the study. Mean age of the study
population was 52.9 years. The majority of
patients were Caucasian (89.7%) and the remain-
der of the population included African descent
(7.7%) and multiple races (2.6%). At screening,
average BMI was 28.91 kg/m2. Dosing groups
were generally comparable with respect to demo-
graphics and baseline characteristics. There was
no signiﬁcant difference in baseline mean TT
levels between SC treatment arms; baseline mean
TT was 214.64 and 201.50 ng/dL for patients in
the 50 and 100 mg arms, respectively. Baseline
mean TT was 735.10 ng/dL for the 200 mg IM
TE group as a result of these patients being main-
tained on their IM regimen at study entry.
PK Profile for T
Figure 2 shows pre-dose and 24 hours post-dose
TT levels collected during the dosing interval.
Patients achieved mean TT levels within the pre-
determined reference range (300–1,100 ng/dL)
within 24 hours following the ﬁrst dose with
either 50 or 100 mg of TE delivered via the self-
administration system. The 50 mg dose of SC TE
provided a temporary increase to T levels, which
fell to baseline between doses (Figure 2). PK
curves in the 50 mg SC group were similar
between weeks 1, 5, and 6 (Figure 3A). Unlike the
50-mg group, T levels rose following the ﬁrst
three doses of 100 mg SC TE. Pre-dose and 24
hours post-dose concentration ranges overlapped
at week 4 and beyond, which is consistent
with having approached steady-state exposure
(Figure 2). At weeks 5 and 6, PK curves for the
100-mg group overlapped and provided greater T
exposure than the exposure observed at week 1
(Figure 3B).
Table 2 summarizes PK parameters by treat-
ment. Both doses of SC TE produced average
steady-state concentrations of T within the normal
range over the dosing interval of 168 hours (7
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days). In contrast, 200 mg IM TE produced supra-
physiologic levels the ﬁrst week after dosing. At
week 6, the 50 mg SC TE treatment group
achieved a Cavg0–168 h (standard deviation [SD] ) of
422.4 ng/dL (123.9), while the 100 mg SC TE
treatment group achieved a Cavg0–168 h (SD) of
895.5 ng/dL (279.8). The IM TE treatment group
achieved a Cavg0–168 h (SD) of 1658.7 ng/dL
(1001.8). Because of rising T levels at later time
points in the 50 mg arm, reliable estimation of
half-life (T1/2) of this dose was not possible. The
apparent T1/2 (SD) was 239.63 hours (59.93) for
100 mg SC TE and 172.57 hours (34.74) for
200 mg IM TE.
SC TE demonstrated dose proportionality as
AUC0–168 h, Cavg0–168 h, Cmax, and minimum observed
plasma concentration (Cmin) of the 100 mg dose of
SC TE were approximately twice those of the
50 mg dose (Table 2). Relative to 200 mg IM TE,
the two doses of 100 mg SC TE (week 5 and week
6 combined) demonstrated similar AUC0-inf, sug-
gesting that the bioavailability of TE is similar
whether administered SC or IM.
PK Profile for DHT and Estradiol
A summary of the main PK parameters for DHT
and estradiol (E2) can be found in Table 2.
Overall, the Cavg0–168 h for each metabolite was
within the reference range (DHT: 4–57.5 ng/dL;
E2: 10–50 pg/mL) for both doses of SC TE. The
Cavg0–168 h for DHT was 30.8 ng/dL and for E2 was
25.6 pg/mL for the 50 mg SC TE group. For the
100 mg SC TE group, Cavg0–168 h for DHT was
51.9 ng/dL and for E2 was 48.3 pg/mL. The Cavg0–
168h for DHT for the 200 mg IM TE group was
117.1 ng/dL. The Cavg0–168 h for E2 for the 200 mg
IM TE group was comparable with that of the
100 mg SC TE group, reaching 50.0 pg/mL. The
ratios of T to metabolites were similar, suggesting
that the conversion rate of T to its metabolites was
similar across groups.
Safety Profile
AEs that occurred during this trial are summarized
in Table 3. No deaths or serious TEAEs were
reported during the course of this study. No study
patient during the course of the study experienced
any cardiovascular events. Thirteen of 39 patients
(33.3%) enrolled in the study reported at least one
TEAE during the course of this trial. Generally,
these TEAEs were of mild to moderate intensity
and only four were reported related to study drug
(Table 4). Two patients in the SC TE arms expe-
rienced insomnia. One patient in the 100 mg SC
Table 1 Patient disposition and baseline demographics/clinical characteristics
Category
Treatment arm
50 mg SC TE 100 mg SC TE 200 mg IM TE Total
Enrolled—n (%) 14 (100) 15 (100) 10 (100) 39 (100)
Mean age (SD) 54.0 (12.4) 54.7 (12.8) 48.9 (10.9) 52.9 (12.1)
Race—n (%)
Caucasian 14 (100) 13 (86.7) 8 (80.0) 35 (89.7)
African descent 0 (0.0) 2 (13.3) 1 (10.0) 3 (7.7)
Multiple 0 (0.0) 0 (0.0) 1 (10.0) 1 (2.6)
Ethnicity—n (%)
Hispanic or Latino 0 (0.0) 0 (0.0) 2 (20.0) 2 (5.1)
Not Hispanic or Latino 14 (100.0) 15 (100.0) 8 (80.0) 37 (94.9)
Enrollment status—n (%)
Treatment naïve 13 (92.9) 13 (86.7)
Requiring washout 1 (7.1) 2 (13.3)
Mean BMI—kg/m2 at screening (SD) 28.51 (2.17) 29.19 (2.87) 29.05 (2.21) 28.91 (2.43)
Mean weight—kg at screening (SD) 91.75 (10.27) 93.16 (12.27) 90.35 (12.03) 91.93 (11.27)
Mean height—cm at screening (SD) 179.21 (4.98) 178.50 (8.39) 176.02 (8.02) 178.12 (7.16)
Mean baseline TT—ng/dL (SD) 214.64 (59.05) 201.50 (71.53) 735.10 (187.96)
Safety population*—n (%) 14 (100) 15 (100) 10 (100) 39 (100)
Pharmacokinetic population†—n (%) 14 (100) 15 (100) 10 (100) 39 (100)
Completed the study—n (%) 14 (100) 15 (100) 9 (90) 38 (97.4)
Discontinued from the study—n (%) 0 (0.0) 0 (0.0) 1 (10.0) 1 (2.6)
Primary reason for discontinuation: Other—n (%) 0 (0.0) 0 (0.0) 1 (10.0) 1 (2.6)
*The safety population consisted of all patients who were randomized to treatment and received at least one dose of study medication. †The pharmacokinetic
population consisted of all patients from the safety population who did not have a major protocol deviation that would impact the integrity of the PK data following
dose administration and had at least one valid plasma concentration value post-dose. For SC TE treatments, baseline TT was the measurement at SV2 for
treatment-naïve patients and the average of measurements at SV2 and SV3 for patients receiving any buccal or transdermal T treatment. If retest of TT happened
because of a sample being ≥300 ng/dL, the average of two of the three samples with TT levels <300 ng/dL was used to calculate the baseline. For the 200 mg IM
TE arm, baseline TT was the measurement at QV. If retest of the QV was needed, the retest value was used for baseline. BMI = body mass index;
IM = intramuscular; PK = pharmacokinetic; QV = qualifying visit; SC = subcutaneous; SD = standard deviation; SV = screening visit; T = testosterone; TE = testos-
terone enanthate; TT = total testosterone
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TE group reported acne. No AEs were reported
from IM TE administration. No TEAE led to
discontinuation from the study. All TEAEs
resolved by the end of the study.
ISA were performed for each injection. Eleven
of 39 patients (28.2%) had no quantiﬁable ISA
observations for all six injections. Almost all ﬁnd-
ings related to injections were transient and
resolved. Only one patient in the 50 mg SC TE
arm experienced an injection site reaction TEAE
(ecchymosis). Thirty-eight of 39 patients reported
no pain on injection; a single patient rated one of
six injections a two on the pain VAS.
Discussion
Although there have been only a few reports in the
literature, these previous studies suggest that the
SC route of administration achieves therapeutic T
levels and is a viable alternative to IM administra-
tion [30–32]. Our article reports the results from a
multicenter, multiple-dose, phase II PK study and
demonstrates that TE in oil-administered SC via a
preﬁlled single-use disposable autoinjector was
able to achieve serum T reliably within reference
ranges over a 1-week dosing interval. Normal T
levels were achieved within hours after ﬁrst dose
and steady-state was approached after the third
dose. SC TEminimized variation in exposure rela-
tive to a chronic 200 mg IM TE dosing cohort.
Mean steady-state Cavg and Cmax T levels were in
the reference range with both doses of SC TE. In
the IM TE cohort, Cavg and Cmax were higher than
normal in the week after dosing. The supra-
physiologic levels of T following 200 mg IM TE is
consistent with prior reports [21,22].
The 50-mg dose exhibited no accumulation
between doses. A similar result at this dose was
demonstrated in healthy men, suggesting that
clearance exceeds exposure by the end of the
dosing interval [33]. The 100 mg SC TE dose
achieved approximately twice the T exposure as
the 50 mg dose; thus demonstrating dose propor-
tionality. Accordingly, DHT and E2 levels
increased with TE dose. The ratio of DHT to T
was similar across the groups, suggesting a similar
rate of metabolism. Overall, the results presented
here suggest that an intermediate dose of 75 mg
weekly will provide optimal T exposure in most
patients.
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The TEAEs reported were mild in nature and
largely unrelated to T or the route of administra-
tion. No TEAEs resulted in discontinuation of the
study. No safety signal emerged from assessment
of TEAEs. Not only does SC administration of
TE appear to be safe for clinical use, but the
TE–autoinjector device combination was well-
tolerated. The TE–autoinjector combination
was not associated with any serious injection
reactions; only one injection site adverse reaction
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(ecchymosis) was reported. A property of our SC
injection systems is reduced or absent sensation of
ﬁne-needle entry and pain. This is likely due to
distraction from pain sensation caused by the force
applied against the skin to retract the safety collar
[34]. Similar to our previous study, pain related to
injection was not present for most patients in this
study. This proﬁle suggests that SC TE injections
will be a well-tolerated treatment for patients.
While the data show that SC TE has a repro-
ducible and dose-proportional PK proﬁle, limita-
tions to this study exist regarding the comparison
with the IM regimen. Randomization of all three
treatment arms, including the IM group, would
have been a more conventional design. This
approach was considered, but not pursued because
of the protracted period of time required to
achieve steady-state with de novo IM TE treatment
dosed every 2 weeks. The purpose of including an
IM arm receiving chronic dosing was to provide
reference PK data reﬂecting the on-label regimen
for TE in contemporary patients and not for
formal statistic comparison.
The advantages of this novel SC TE
autoinjector combination product are numerous.
This delivery method effectively restores physi-
ologic levels of T in patients with hypogonadism.
The device is designed to produce accurate
and rapid dosing, as a 0.5 mL injection of drug
occurs in less than 5 seconds, and reduces the
risk for medication abuse. While patients in this
study did not self-administer medication, in
other (unpublished) device use studies, men with
hypogonadism report that this device is easy to
use, and home self-administration will be assessed
in long-term therapeutic studies. Further, the
risk of passive transference to women and chil-
dren associated with topical gels is eliminated
with SC TE [10]. As peak to trough variability
is reduced with weekly SC TE, there may be
less risk for treatment-related mood swings
seen with IM TE [9,23]. A weekly regimen of SC
TE, and the convenience and ease of use of
at-home self-administration may lead to higher
patient compliance than daily dosing regimens
[35].
Table 3 Overview of adverse events*
Patients with AEs
50 mg SC TE
(n = 14)
100 mg SC TE
(n = 15)
200 mg IM TE
(n = 10)
n (%) n (%) n (%)
Patients with a TEAE
Any TEAE 6 (42.9) 7 (46.7) 0 (0.0)
Any drug-related TEAE 2 (14.3) 2 (13.3) 0 (0.0)
Patients with an SAE 0 (0.0) 0 (0.0) 0 (0.0)
Treatment–emergent SAE 0 (0.0) 0 (0.0) 0 (0.0)
Drug-related SAE 0 (0.0) 0 (0.0) 0 (0.0)
Deaths 0 (0.0) 0 (0.0) 0 (0.0)
Discontinuations because of TEAE 0 (0.0) 0 (0.0) 0 (0.0)
*An AE was considered to be a TEAE if the AE started on or after the first dosing of study medication. Percentage was calculated using the number of patients
in the column heading as the denominator. AE = adverse event; IM = intramuscular; SAE = serious adverse event; SC = subcutaneous; TE = testosterone
enanthate; TEAE = treatment-emergent adverse event
Table 4 Drug-related treatment-emergent adverse events*
System organ class (preferred term)
50 mg SC TE
(n = 14)
100 mg SC TE
(n = 15)
200 mg IM TE
(n = 10)
n (%) n (%) n (%)
Patients with any drug-related TEAE 2 (14.3) 2 (13.3) 0 (0.0)
General disorders and administration site conditions 1 (7.1) 0 (0.0) 0 (0.0)
Injection site hemorrhage† 1 (7.1) 0 (0.0) 0 (0.0)
Psychiatric disorders 1 (7.1) 1 (6.7) 0 (0.0)
Insomnia 1 (7.1) 1 (6.7) 0 (0.0)
Skin and subcutaneous tissue disorders 0 (0.0) 1 (6.7) 0 (0.0)
Acne 0 (0.0) 1 (6.7) 0 (0.0)
*An AE was considered to be a TEAE if the AE started on or after the first dosing of study medication. Percentage was calculated using the number of patients
in the column heading as the denominator. Although a patient may have had two or more TEAEs, the patient was counted only once within a system organ class
category. The same patient may have contributed to two or more preferred term categories. †Injection site ecchymosis (reported term of “left abdominal injection
site ecchymosis”, and coded as “injection site ecchymosis” as lower level term and “hemorrhage” as the preferred term because of MedDRA coding specifications).
AE = adverse event; IM = intramuscular; SC = subcutaneous; TE = testosterone enanthate; TEAE = treatment-emergent adverse event
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Conclusion
Once approved by the FDA, the combination
product of TE in oil-administered SC via a novel,
preﬁlled, disposable autoinjector, which was devel-
oped to deliver high-viscosity solutions through a
small-gauge needle, will provide a simple and well-
tolerated method for SC self-administration of
TE. The safety proﬁle was benign. The overall
results of this study indicate that SC TE delivered
in this fashion has acceptable tolerability with a
reproducible and dose-proportional PK proﬁle.
The outcomes of this phase II study warrant pro-
ceeding to a larger phase III study. Furthermore,
dose proportionality supports the predictability of
exposure to an intermediate dose of TE and sug-
gests the feasibility of dose adjustment based on T
levels.
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Figure S1 Subcutaneous testosterone enanthate autoinjector
device. The autoinjector is designed to eject high-viscosity solu-
tions from a preﬁlled syringe ﬁtted with a ﬁve-eighths-inch
27-gauge needle
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